A new paper in BJS, published by Oxford University Press, indicates that early-onset gastrointestinal cancer rates are rising dramatically across the globe.

Among other TAAs explored for dual signaling inhibitors, one of the major areas of development is represented by the HER2, whose overexpression is a major driver in various solid tumors, such as ...